Sun and Ranbaxy marriage puts Sun founder Shanghvi in position to influence industry

Sun Pharma Managing Director Dilip Shanghvi

The combo of Sun Pharmaceutical and Ranbaxy Laboratories just weeks ago created a significant force in the global generics market by any number of measures. It is India's largest drugmaker by far and the largest Indian drugmaker selling into the U.S. market. It is the fifth-largest generic company globally with combined sales of $4.2 billion. While it is significantly smaller than leader Teva Pharmaceutical ($TEVA) with more than $20 billion in annual revenues, Sun is large enough to be a significant force. All of this bestows on Sun founder and managing director Dilip Shanghvi new influence in the global pharma industry. As such, he is included in this year's FierceBiotech's The 25 most influential people in biopharma in 2015. Check out the report and see who else is on the list with Shanghvi. Report

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.